NCT02185053View on ClinicalTrials.gov

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

CPC-201

Trial Locations (1)

Unknown

CPC1, West Palm Beach

All Listed Sponsors
lead

Chase Pharmaceuticals Corporation, an affiliate of Allergan plc

INDUSTRY

NCT02185053 - A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia | Biotech Hunter | Biotech Hunter